The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation
Authors:
- 21 January 2023
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 116, 109704
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the Chikungunya virus in BEAS-2B cellsVirology Journal, 2012
- Immunogenicity to Therapeutic Proteins: Impact on PK/PD and EfficacyThe AAPS Journal, 2012
- Immunogenicity and other problems associated with the use of biopharmaceuticalsTherapeutic Advances in Drug Safety, 2011
- Immunogenicity of protein therapeutics: The key causes, consequences and challengesSelf/Nonself, 2010
- CD19: a promising B cell target for rheumatoid arthritisNature Reviews Rheumatology, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- B lymphocytes: how they develop and functionBlood, 2008
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptorsProceedings of the National Academy of Sciences of the United States of America, 2008
- Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirusProceedings of the National Academy of Sciences, 2006
- RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangementCell, 1992